MT-125 Inhibits Non-Muscle Myosin IIA & IIB, Synergizes with both Radiation & Oncogenic Kinase Inhibitors & Prolongs Survival in Glioblastoma
Time: 2:30 pm
day: Conference Day 2
Details:
- MT-125 increases cytoplasmic ROS, induces DNA damage and ferroptosis, prolongs survival in murine GBM models as a monotherapy, and synergizes with radiation.
- MT-125 stimulates oncogenic kinase signaling in glioblastoma through a novel ROSdriven mechanism that induces oncogene addiction, creating synthetic lethality when it is combined with oncogenic kinase inhibitors.
- Combining MT-125 with an FDA-approved PDGFR inhibitor in a murine GBM model significantly improves median survival over either drug alone, and produces prolonged survival in over 40% of mice.
